Search results for "Dermatology"

Abstract We have read with great interest Dr Recalcati’s review about skin manifestations in COVID‐19 as it is the first report on this subject1. In a recent review on clinical characteristics of coronavirus disease 2019 in China, rash was observed in 0,2% of cases2. However, from the trained eyes of a dermatologist, this percentage may be higher.

2019-20 coronavirus outbreakmedicine.medical_specialtyskinCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DermatologyLetter to Editor030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineCOVID‐19medicineSkin manifestationscutaneous manifestationsbusiness.industrycutaneousmedicine.diseaseDermatologyRashPneumoniaInfectious Diseases030220 oncology & carcinogenesisDifferential diagnosismedicine.symptombusinessCoronavirus InfectionsJournal of the European Academy of Dermatology and Venereology

researchProduct

205th ENMC International Workshop: Pathology diagnosis of idiopathic inflammatory myopathies Part II 28-30 March 2014, Naarden, The Netherlands.

2015

The idiopathic inflammatory myopathies (IM) are a heterogeneous group of diseases and diagnosis often necessitates a muscle biopsy. Five main entities are recognized: (1) dermatomyositis (DM); (2) polymyositis (PM); (3) necrotizing autoimmune myopathy (NAM); (4) sporadic inclusion body myositis (IBM); and (5) non-specific myositis. Other entities include granulomatous myopathy, macrophagic myofasciitis, and eosinophilic fasciitis (Shulman's syndrome). The pathological classification and subsequent identification of disease subgroups are extremely important for assessing treatment options and prognosis in the individual patient, yet classification criteria have not been standardized and vali…

2716 Genetics (clinical)medicine.medical_specialtyConsensusBiopsy10208 Institute of Neuropathology610 Medicine & healthPolymyositismedicineHumans2735 Pediatrics Perinatology and Child HealthColoring AgentsMyopathyGenetics (clinical)MyositisNetherlandsMuscle biopsyMyositismedicine.diagnostic_testbusiness.industryMusclesMacrophagic myofasciitisDermatomyositismedicine.diseaseDermatologyEosinophilic fasciitis2728 Neurology (clinical)Neurology2808 NeurologyPediatrics Perinatology and Child HealthPhysical therapy570 Life sciences; biologyNeurology (clinical)medicine.symptomInclusion body myositisbusinessNeuromuscular Disorders

researchProduct

The effect of bergamot on dyslipidemia

2016

Abstract Background Statins are the most common used lipid lowering drugs but they may cause adverse effects and despite their well-established therapeutic benefits residual cardiovascular (CV) risk remains. The use of other lipid lowering drugs and nutraceuticals alone or as add-on lipid-modifying therapy can be an option in such cases. Several studies have reported health-related properties of the Citrus fruits, among which bergamot (Citrus bergamia Risso) differs from others by particularly high content of certain compounds. Purpose This narrative review summarizes the current evidence on the effects of bergamot on lipid parameters based on studies involving animals and humans. Main evid…

3003CitrusFuture studiesBergamotPharmaceutical Science030204 cardiovascular system & hematologyBioinformatics01 natural sciences03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalDrug DiscoverymedicineAnimalsHumansAdverse effectDyslipidemiasHypolipidemic AgentsFlavonoidsPharmacologyPlant ExtractsChemistryCholesterolMedicine (all)Drug Discovery3003 Pharmaceutical ScienceCardiovascular riskComplementary and Alternative Medicine2708 Dermatologymedicine.disease0104 chemical sciences010404 medicinal & biomolecular chemistryDyslipidemiaComplementary and alternative medicineBiochemistryLDL cholesterolCitrus bergamiaMolecular MedicineNarrative reviewLipid loweringDyslipidemiaPhytomedicine

researchProduct